People: Idera Pharmaceuticals Inc (IDRA.OQ)

IDRA.OQ on NASDAQ Stock Exchange Capital Market

3.09USD
10:01am EST
Price Change (% chg)

$0.29 (+10.36%)
Prev Close
$2.80
Open
$2.85
Day's High
$3.13
Day's Low
$2.85
Volume
129,178
Avg. Vol
185,021
52-wk High
$6.87
52-wk Low
$1.94

Search Stocks

Summary

Name Age Since Current Position

James Geraghty

60 2013 Chairman of the Board

Sudhir Agrawal

60 2013 President, Chief Executive Officer, Director

Youssef El Zein

65 1997 Independent Vice Chairman of the Board

Louis Arcudi

53 2011 Chief Financial Officer, Senior Vice President - Operations, Treasurer, Secretary

Louis Brenner

44 2014 Senior Vice President, Chief Medical Officer

William Reardon

68 2010 Lead Independent Director

Julian Baker

48 2014 Director

Mark Goldberg

60 2014 Director

Kelvin Neu

41 2014 Director

Robert Karr

65 2007 Independent Director

Malcolm MacCoss

66 2010 Independent Director

Eve Slater

68 2010 Independent Director

Biographies

Name Description

James Geraghty

Mr. James A. Geraghty has been appointed as Chairman of the Board of Idera Pharmaceuticals Inc., effective July 8, 2013. Mr. Geraghty also served as a Senior Vice President of Sanofi SA following its acquisition of Genzyme, and recently took on a role as an Entrepreneur-in-Residence at Third Rock Ventures. Currently an Entrepreneur-in-Residence at Third Rock Ventures, Jim served as Senior Vice President, North America Strategy and Business Development at Sanofi, where he was a member of the Office of the CEO. Prior to Sanofi’s acquisition Jim spent 20 years at Genzyme Corporation, most recently as Senior Vice President, and helped Genzyme introduce rare disease therapies around the world. His roles included President of Genzyme Europe, where he oversaw several new product launches, and General Manager of Genzyme’s cardiovascular business, where he guided the development of a recently approved antisense product. He also led strategic transactions that brought important new products into Genzyme, as well as divestitures valued at over $1 billion. He was previously Chairman, President and CEO of Genzyme Transgenics Corporation (later GTC Biotherapeutics), which he founded and took public. Jim served as co-chair of the executive committee for BIO 2007, was for a number of years a member of the board of Bluebird Bio, and continues to serve on the board of Bio Ventures for Global Health (BVGH). A graduate of the Yale Law School, he has published articles in the Yale Law Journal, Health Affairs and elsewhere. He holds an MS from the University of Pennsylvania and a BA from Georgetown University.

Sudhir Agrawal

Dr. Sudhir Agrawal,D. Phill., is President, Chief Executive Officer, Director of Idera Pharmaceuticals Inc. He is a director since 1993, has served as the chairman of the board of directors since September 2010, President since September 2008 and Chief Executive Officer since August 2004. He served as Chief Scientific Officer from January 1993 until September 2010, as President from February 2000 to October 2005 and as Acting Chief Executive Officer from February 2000 until September 2001. Dr. Agrawal joined the Company in 1990 and served in various capacities before his appointment as Chief Scientific Officer, including Vice President of Discovery and Senior Vice President of Discovery. Prior to joining the Company, Dr. Agrawal served as a Foundation Scholar at the Worcester Foundation for Experimental Biology and carried out his post-doctoral research at the Medical Research Council’s Laboratory of Molecular Biology in Cambridge, England from 1985 to 1986.

Youssef El Zein

Mr. Youssef El Zein is an Independent Vice Chairman of the Board of Idera Pharmaceuticals Inc. Mr. El Zein is a director since 1992, has been the Managing Partner of Pillar Invest Corporation. Mr. El Zein has been the chairman and CEO of Pillar Invest (offshore) SAL since 2009. Mr. El Zein has been managing partner of Pillar Investment Limited, a private investment firm, since 1991. Mr. El Zein obtained his Bachelor of Arts in Economics from the American University of Beirut in 1970 and a postgraduate degree in Economics from St Catherine’s College, Oxford University in 1973.

Louis Arcudi

Mr. Louis J. Arcudi,III., is Chief Financial Officer, Senior Vice President - Operations, Treasurer, Secretary of Idera Pharmaceuticals Inc. He has been Senior Vice President of Operations since April 2011 and Chief Financial Officer, Treasurer and Secretary since he joined the Company in December 2007. Prior to joining the Company, Mr. Arcudi served as Vice President of Finance and Administration and Treasurer for Peptimmune, Inc., a biotechnology company, from 2003 to 2007. From 2000 to 2003 Mr. Arcudi was Senior Director of Finance and Administration at Genzyme Molecular Oncology Corporation, a division of Genzyme Corporation, a biotechnology company. He was Director of Finance Business Planning and Operations International at Genzyme from 1998 to 2000. Prior to joining Genzyme, he held finance positions with increasing levels of responsibility at Cognex Corporation, a supplier of machine vision systems, Millipore Corporation, a provider of technologies, tools and services for bioscience, research and biopharmaceutical manufacturing, and General Motors Corporation, an automobile manufacturer. Mr. Arcudi received a M.B.A. from Bryant College and a B.S. in accounting and information systems from the University of Southern New Hampshire.

Louis Brenner

Dr. Louis Brenner, M.D., is Senior Vice President and Chief Medical Officer of the Company. Dr. Brenner commenced employment with the Company on January 6, 2014. Prior to joining the Company, Dr. Brenner served as Senior Vice President and Chief Medical Officer of Radius Health, Inc., a biopharmaceutical company, from November 2011 to January 2014. From September 2006 to December 2010, Dr. Brenner was Senior Vice President at AMAG Pharmaceuticals, a biotechnology company. From June 2002 to September 2006, Dr. Brenner served in progressively senior roles at Genzyme Corporation, a biotechnology company. Dr. Brenner holds a B.S. in Biology from Yale University, an M.D. from Duke University and an M.B.A. from Harvard Business School.

William Reardon

Mr. William S. Reardon,CPA., is Lead Independent Director of Idera Pharmaceuticals Inc., since September 2010. He is a director since 2002. He was an audit partner at PricewaterhouseCoopers LLP, where he led the Life Science Industry Practice for New England and the Eastern United States from 1986 until his retirement from the firm in July 2002. Mr. Reardon served on the board of the Emerging Companies Section of the Biotechnology Industry Organization from June 1998 to June 2000 and the board of directors of the Massachusetts Biotechnology Council from April 2000 to April 2002. He serves as a director of Synta Pharmaceuticals, Inc., a publicly-traded biopharmaceutical company, and he served as a director of Oscient Pharmaceuticals Corporation, a publicly-traded pharmaceutical company from March 2003 to March 2010. Mr. Reardon has served as a trustee of closed-end mutual funds H&Q Healthcare Investors and H&Q Life Sciences Investors since April 2010.

Julian Baker

Mr. Julian C. Baker is Director of the Company. Julian C. Baker is a Managing Partner of Baker Brothers Investments. Mr. Baker is currently a Director of Genomic Health, Inc. and Incyte Corporation, Inc.

Mark Goldberg

Dr. Mark Goldberg, M.D., is Director of the Company. He has served as Senior Vice President for Medical and Regulatory Affairs at Synageva BioPharma since September 2011. Before joining Synageva, he served in management capacities of increasing responsibility at Genzyme from 1996 to 2011, including most recently as Senior Vice President for Clinical Development and Global Therapeutic Group Head for Oncology and Personalized Genetic Health. While at Genzyme, Dr. Goldberg played a key role in the development and approval of four successful orphan therapies: Fabrazyme®, Aldurazyme®, Myozyme® and Lumizyme®. Prior to joining Genzyme, he was a full-time staff physician at Brigham and Women’s Hospital and the Dana-Farber Cancer Institute, where he still holds appointments. Dr. Goldberg is a board-certified medical oncologist and hematologist and has published more than 50 papers.

Kelvin Neu

Dr. Kelvin Neu is Director of the Company. Kelvin M. Neu, M.D., is a Managing Director of Baker Brothers Investments. A physician, Dr. Neu also serves as a Director of XOMA Corporation and Presidio Pharmaceuticals, Inc.

Robert Karr

Dr. Robert W. Karr,M.D., is Independent Director of Idera Pharmaceuticals Inc., since 2005. He has been Managing Member of StartUp Partners International LLC, a consulting firm serving pharmaceutical and biotechnology clients since January 2010. Dr. Karr has served as managing director of Karr Pharm Consulting LLC since January 2008. Dr. Karr served as the President from December 2005 until December 2007. Prior to joining the Company, Dr. Karr was an independent consultant. From June 2000 through December 2004, Dr. Karr was a senior executive in Global Research & Development for Pfizer, Inc., a pharmaceutical company, where he served as Senior Vice President, Strategic Management from 2003 to 2004 and Vice President, Strategic Management from 2000 to 2003. Prior to its merger with Pfizer, Dr. Karr served as Vice President, Research & Development Strategy for Warner-Lambert Company, a pharmaceutical company. He served on the board of directors of GTx, Inc., a publicly-traded biotechnology company, from 2005 to 2011.

Malcolm MacCoss

Dr. Malcolm MacCoss,Ph.D., is Independent Director of Idera Pharmaceuticals Inc., since January 2010. Dr. MacCoss founded Bohicket Pharma Consulting LLC in January 2010. In this position, Dr. MacCoss consults for several pharmaceutical companies worldwide on drug discovery issues. Previously, Dr. MacCoss served as the Group Vice President for Chemical Research at the Schering-Plough Research Institute of Schering-Plough Corporation, a pharmaceutical company that is now part of Merck & Co., Inc., from August 2008 to January 2010. In this role he served as the Head of Chemistry at the Schering-Plough Kenilworth, New Jersey site and as the chair of the Schering-Plough Global Chemistry Council, a forum for formulating global chemistry strategies. From 1999 to August 2008, Dr. MacCoss served as Vice President, Basic Chemistry at the Rahway, New Jersey site of Merck Research Laboratories, of Merck & Co., Inc., a pharmaceutical company. He served as the Vice President of Basic Chemistry and Drug Discovery Sciences, as the Deputy Site-Head of the Rahway site and as the Chairman of the Merck World-Wide Chemistry Council. Dr. MacCoss is a Fellow of the Royal Society of Chemistry, and in 2009 he was admitted into the American Chemical Society Medicinal Chemistry Hall of Fame. In 2010 he received the ACS Division of Medicinal Chemistry National Award. He serves on the Advisory Committee of the Executive Dean for the School of Arts and Sciences, Rutgers University.

Eve Slater

Dr. Eve E. Slater,M.D., is Independent Director of Idera Pharmaceuticals Inc., since 2010. She is Associate Professor of Clinical Medicine at Columbia University College of Physicians and Surgeons, where she has taught in positions since 1983. Dr. Slater was Senior Vice President, Worldwide Policy at Pfizer, Inc. from May 2007 until June 2009. Dr. Slater was the Assistant Secretary for Health, United States Department of Health and Human Services from 2002 until 2003, and was the Acting Assistant Secretary for Health from 2001 until her confirmation by the United States Senate in 2002. Dr. Slater held senior management positions at Merck Research laboratories from 1983 to 2001, including Senior Vice President of External Policy, Vice President of Corporate Public Affairs, Senior Vice President of Clinical and Regulatory Development, Executive Director of Biochemistry and Molecular Biology, and Senior Director of Biochemical Endocrinology. Dr. Slater was trained in Internal Medicine and Cardiology at Massachusetts General Hospital, is board certified in Internal Medicine and Cardiology and is a Fellow of the American College of Cardiology.

Basic Compensation

Options Compensation

Search Stocks